Amb motiu del tancament d'estiu, la validació de documents es reprendrà a partir del 28 d'agost de 2026. Disculpeu les molèsties.
Con motivo del cierre de verano, la validación de documentos se reanudará a partir del 28 de agosto de 2026. Disculpad las molestias
Due to the summer closure, document validation will resume starting August 28, 2026. We apologize for any inconvenience.

Fitxers

641597.pdf (844.68 KB)

Tipus de document

Article

Versió

Versió publicada

Data de publicació

2014-01-27

Llicència de publicació

cc-by (c) Kawana-Tachikawa, Ai et al., 2014
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/109602

Effect of Maraviroc intensification on HIV-1-specific T cell immunity in recently HIV-1-infected individuals

Títol de la revista

Autors

Director/Tutor

ISSN de la revista

Títol del volum

Recurs relacionat

https://doi.org/10.1371/journal.pone.0087334

Resum

BACKGROUND: The effect of maraviroc on the maintenance and the function of HIV-1-specific T cell responses remains unknown. METHODS: Subjects recently infected with HIV-1 were randomized to receive anti-retroviral treatment with or without maraviroc intensification for 48 weeks, and were monitored up to week 60. PBMC and in vitro-expanded T cells were tested for responses to the entire HIV proteome by ELISpot analyses. Intracellular cytokine staining assays were conducted to monitor the (poly)-functionality of HIV-1-specific T cells. Analyses were performed at baseline and week 24 after treatment start, and at week 60 (3 months after maraviroc discontinuation). RESULTS: Maraviroc intensification was associated with a slower decay of virus-specific T cell responses over time compared to the non-intensified regimen in both direct ex-vivo as well as in in-vitro expanded cells. The effector function profiles of virus-specific CD8⁺ T cells were indistinguishable between the two arms and did not change over time between the groups. CONCLUSIONS: Maraviroc did not negatively impact any of the measured parameters, but was rather associated with a prolonged maintenance of HIV-1-specific T cell responses. Maraviroc, in addition to its original effect as viral entry inhibitor, may provide an additional benefit on the maintenance of virus-specific T cells which may be especially important for future viral eradication strategies.

Matèries

Cèl·lules T, VIH (Virus), Antiretrovirals, Resposta immunitària, Genètica molecular

Matèries (anglès)

T cells, HIV (Viruses), Antiretroviral agents, Immune response, Molecular genetics

Citació

Col·leccions

Articles publicats en revistes (Medicina)

Citació

KAWANA-TACHIKAWA, Ai, et al. Effect of Maraviroc intensification on HIV-1-specific T cell immunity in recently HIV-1-infected individuals. PLoS One. 2014. Vol. 9, num. 1, pags. e87334. ISSN 1932-6203. [consulted: 3 of August of 2026]. Available at: https://hdl.handle.net/2445/109602

Exportar metadades

JSON - METS

Compartir registre